Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

@article{Carr2002AbacavirSF,
  title={Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.},
  author={Andrew Carr and Cassy Workman and Don E. Smith and Jennifer Hoy and Jeff D Hudson and Nicholas Doong and Allison Martin and J Amin and Judith Freund and Matthew V. Law and David A. Cooper},
  journal={JAMA},
  year={2002},
  volume={288 2},
  pages={207-15}
}
CONTEXT Peripheral lipoatrophy may complicate antiretroviral therapy of human immunodeficiency virus (HIV) infection, often related to duration and type of nucleoside analog therapy, and may have a mitochondrial pathogenesis. No proven therapy exists for lipoatrophy, but abacavir is a nucleoside analog that may be less toxic to mitochondria. OBJECTIVE To determine if substitution of stavudine or zidovudine with abacavir improves HIV lipoatrophy without affecting control of HIV replication… CONTINUE READING